CurrentCignaPolicy N/A

Orencia (abatacept) intravenous prior authorization / coverage form

This document is a Cigna prior authorization/coverage form for Orencia vial (intravenous abatacept) used across multiple indications (RA, JIA, PsA, AS, IBD, GvHD, psoriasis). It governs documentation and prior authorization requirements for providers requesting coverage and administration setting details.

Policy Summary

PayerCigna

PolicyOrencia (abatacept) intravenous prior authorization / coverage form

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization with required documentation of prior therapies, trial durations, and objective response measures using the Cigna form.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

250mgvial size requested on form

6 monthscontinuation threshold

90 daysOrencia IV established duration

5 daysstandard response time

Coverage Criteria by Indication

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria by indication

Covered when the following indication-specific requirements are met. Approval generally requires documentation of prior therapies, objective clinical response measures, and appropriate prescriber specialty/consultation as indicated below.

General authorization requirements: Provider must complete form fields including patient identifiers, indication, dose, J-code, administration setting, and provide documentation of prior therapies and responses.

Attach medical documentation (chart notes, prescription claims, receipts) showing prior trials and responses; missing documentation may result in denial.

Rheumatoid arthritis (RA)

Improvement in at least one symptom (e.g., decreased joint pain, morning stiffness, fatigue), improved function or ADLs, or decreased soft tissue swelling.
See examples in form (chunk 9).
Trial of at least one conventional synthetic DMARD (oral or injectable; e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) for at least 3 months.>= 3 months
(chunk 9).
Trial of at least one biologic other than the requested drug for at least 3 months; a biosimilar of the requested biologic does not count as a prior biologic.>= 3 months
Examples of biologics listed on form (etanercept, adalimumab products, infliximab, tocilizumab, rituximab, etc.).
Documented beneficial clinical response assessed by at least one objective measure (e.g., CDAI, DAS28-ESR/CRP, PAS-II, RAPID-3, SDAI).
(chunk 9).
Requested medication prescribed by or in consultation with a rheumatologist.
(chunk 9).

Juvenile idiopathic arthritis (JIA)

Documented beneficial clinical response by at least one objective measure (e.g., MD global, PGA, PDA, JDAS, cJDAS, JSpADA, serum markers, or reduced corticosteroid dose).
(chunk 11).
Improvement in at least one symptom vs baseline (e.g., motion limitation, joint pain/tenderness, morning stiffness, fatigue, improved function/ADLs).
(chunk 11).
Per prescriber, established on Orencia IV for at least 90 days if IV formulation (answer NO if only on SC formulation).Orencia IV >= 90 days
(chunk 11).
Tried at least one other agent (examples: methotrexate, sulfasalazine, leflunomide, NSAID) OR a biologic (other than requested); or documentation of absolute contraindication to methotrexate/sulfasalazine/leflunomide if starting without combination therapy.>= 1 prior agent

Psoriatic arthritis (PsA)

Documented beneficial clinical response by at least one objective measure (e.g., DAPSA, CPDAI, PsA DAS, Grace Index, LEI, SPARCC, Leeds Dactylitis Instrument, MDA, PsAID-12, or serum markers).
(chunk 14).
Improvement in at least one symptom vs baseline (e.g., less joint pain, morning stiffness, fatigue, improved function/ADLs, decreased soft tissue swelling).
(chunk 14).
Per prescriber, established on Orencia IV for at least 90 days if IV formulation (answer NO if only on SC formulation).Orencia IV >= 90 days
(chunk 14).
Trial of one or more of the listed alternative therapies (examples include adalimumab products, Bimzelx, Cimzia, Cosentyx, Enbrel, infliximab products, Otezla, Rinvoq, Simponi, Skyrizi, Taltz, Tremfya, ustekinumab products, Xeljanz), with medical documentation attached.
A trial of multiple products within a single agent class (e.g., multiple adalimumab products) counts as one product per form instructions (chunk 15).

Graft-versus-host disease (GvHD) - prevention

Intent that Orencia is being used for prevention of acute graft-versus-host disease.
(chunk 17).
Concurrent planned use of a calcineurin inhibitor (e.g., cyclosporine, tacrolimus) and whether methotrexate will also be used.
(chunk 17).
Donor type documented as matched unrelated donor or 1-allele-mismatched unrelated donor when applicable.
(chunk 17).
Requested medication prescribed by or in consultation with an oncologist, hematologist, or a physician affiliated with a transplant center.
(chunk 17).

Per the form, the provider must document the planned administration setting (home, physician office, hospital outpatient, or other) and consider the least intensive medically appropriate setting for infusion. Some Cigna plans require that infusions occur in that least intensive setting, and the form asks whether the patient is a candidate for re-direction to an alternate lower-intensity site (for example, alternate infusion site, physician office, or home) with assistance from a Specialty Care Options Case Manager. If re-direction is not appropriate, the provider should supply a medical necessity rationale on the form.

The form notifies providers that medical documentation specific to prior trials must be attached or the request could be denied. Acceptable documentation includes chart notes, prescription claims records, and prescription receipts, and all documentation must include patient-identifying information. Failure to provide these attachments or to meet the specified prior-therapy or objective-response criteria may result in denial of the request.

Billing and Coding

Billing code placeholdermixed

J-code

Field present on form for drug billing J-code (exact code not specified on form)

Required durations or trial lengths

Conventional DMARD trial lengthAt least 3 months of a conventional synthetic DMARD (e.g., methotrexate, leflunomide, sulfasalazine) is required for many indications.

Established on Orencia (overall)Patient established on Orencia (intravenous or subcutaneous) for at least 6 months for continuation/coverage consideration.

Established on Orencia IV (JIA, PsA, others as specified)Patient established on Orencia IV (intravenous formulation) for at least 90 days when the IV formulation is being used; answer NO if patient has only received SC formulation.

Restarting therapyIf the patient is restarting therapy and has received less than 6 months of prior therapy, they are considered not established (answer NO).

Prior Authorization & Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Orencia (abatacept) prior to administration. The prior authorization form must collect dose, J‑code, administration setting, frequency, duration of therapy, and patient weight/requested mg/kg dose as applicable. Submit requests online at covermymeds.com or via SureScripts in your EHR when available.

Collectrequested medication, dose/quantity, duration, J‑code, frequency, ICD‑10, current weight, requested mg/kg dose

Documentation Required

Required Supporting Documentation

Attach all medical records and supporting documentation to the prior authorization request. Required documentation includes chart notes, prescription claims records, and/or prescription receipts that verify prior medication trials, dates, duration, and clinical response. Documentation must include patient‑specific identifying information. Missing documentation may delay processing or result in denial.

Chart notes showing dates and duration of prior therapies
Prescription claims or receipts confirming trials and dates
Objective disease activity measures (e.g., CDAI, DAS28, RAPID‑3) when applicable

Denial Risk

Missing Documentation May Trigger Denial

Absence of required, case‑specific documentation — for example, lack of records confirming prior DMARD or biologic trials, missing duration of therapy, or absent objective clinical response measures — may result in denial of the request. Ensure all checklist items referenced on the form are supported by attached records.

Missing trial documentation for conventional synthetic DMARDs or prior biologic therapies risks denial
Lack of objective outcome measures after prior therapy (when requested) risks denial
Incomplete administration setting or dosing information may trigger denial or request for more information

Background

Orencia (abatacept) intravenous is requested on the form for autoimmune inflammatory conditions such as rheumatoid arthritis and related disorders. The form collects indication-specific information including prior therapies tried (lists of conventional and biologic agents), objective measures of clinical response, and documentation of symptom improvement versus baseline to determine medical necessity for IV abatacept.

Definitions

Biologic (as defined on the form)

DefinitionBiologic: agents listed on the form including adalimumab products (Humira, biosimilars), etanercept SC products (Enbrel, biosimilar), infliximab IV products (Remicade, biosimilar), rituximab IV products (Rituxan, biosimilar), tocilizumab products (Actemra, IV or SC, biosimilar), and others such as Bimzelx, Cimzia, Cosentyx, Entyvio, Ilumya, Kevzara, Kineret, Omvoh, Orencia SC, Skyrizi, Siliq, Simponi, Taltz, Tremfya, ustekinumab products (Stelara), and Zymfentra.

Examples - TNF inhibitorsAdalimumab products (Humira, Abrilada, biosimilars), etanercept (Enbrel, biosimilar), infliximab IV products (Remicade, biosimilar), and certifiable biosimilars.

Examples - IL and other biologicsIL-17/IL-23 and other biologic agents listed include Cosentyx, Taltz, Skyrizi, Tremfya, Stelara (ustekinumab), Ilumya, and others noted on the form.

Policy Summary

PayerCigna

PolicyOrencia (abatacept) intravenous prior authorization / coverage form

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization with required documentation of prior therapies, trial durations, and objective response measures using the Cigna form.

SourceLink

On This Page

Requested medication prescribed by or in consultation with a rheumatologist.

(chunks 11,12).

Prescribed by or in consultation with an appropriate specialist (rheumatologist or dermatologist as applicable).

(chunks 14,15).